Positive MAPLE data for abicipar, promising research data for Molecular Partners’ innovative oncology DARPin® candidates presented; Recruitment hold in MP0250 NSCLC trial; Ongoing focus on multiple myeloma for MP0250 clinical development
Zurich-Schlieren, May 9, 2019. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech
company that is developing a new class of drugs known as DARPin® therapies*, announced today
its Interim Management Statement for the period ending March 31, 2019.
“Our team is focused on delivering on our strategic priorities by advancing clinical candidates
MP0250 and MP0274 and by bringing our first immuno-oncology compound MP0310 to patients
with our partner Amgen,” said Dr. Patrick Amstutz, CEO of Molecular Partners. “Additionally, our
pioneering early-stage pipeline — including a tumor-localized CD40 activator (FAP x CD40), pMHCcomplex targeting with DARPin® molecules, DARPin® CD3 platform and DARPin® drug conjugates
— promises to break new ground in their therapeutic space and to further augment our robust
DARPin® platform.”